31st Pharmacovigilance 2023

31st Pharmacovigilance 2023

“Latest developments in pharmacovigilance, drug safety & risk management”

01-02 February 2023, Radisson RED London Heathrow, UK

Virtue Insight is glad to invite people to attend as a delegate/sponsor for 31st Pharmacovigilance 2023 which is happening on 01-02 February 2023, Radisson RED London Heathrow, UK.

Please contact Kavitha at E-mail -kavitha@virtueinsight.co.in  or call +44 20 3509 3779

DELEGATE REGISTRATION:

STANDARD PRICE

1 Delegate @ £1299 + VAT

Group Discount @ £2598 + VAT (3 Delegates for the price of 2)

SPONSORS:

Gold Sponsor – Pharsafer

Silver Sponsor - Qinecsa Solutions, CLINEXEL Life Sciences

Bronze Sponsor - Quanticate, Brookwood Global

We have sponsorship opportunities available for the event, which gives you an opportunity to speak/exhibit, and create brand awareness.  Here you can have a dedicated networking time, meet the leading international vendors and expand your knowledge of the latest business models. Please email to kavitha@virtueinsight.co.in  for more details.

KEY SPEAKERS:

• KHAUDEJA BANO, Vice President, Combination Product Quality, Amgen
• SIDDHARTH CHACHAD, Executive Vice President & Head - Global Clinical Management, Dr. Reddy’s Laboratories
• JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi
• MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Johnson & Johnson
• SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda Pharmaceuticals
• YVONNE NANCIU, Country Head Pharmacovigilance, Bayer
• ADI MEISTER, PV Sr. Manager, Teva
• ROBERT MASSOUH, Director - Risk Management Product Lead, Pfizer
• HUMAIRA QURESHI, CEO, Qinecsa Solutions
• RISHI CHOPRA, Global Head of Pharmacovigilance Regions, CSL Behring
• PAV RISHIRAJ, Director – Pharmacovigilance & ABPI PV Expert Chair, Ipsen
• TARAK THAKKER, Director, Safety Systems, BeiGene (USA)
• ELIAN KHAZNEH, Head of Global Patient Safety Benefit Risk Strategy & Mgmt, Merck Healthcare
• FABIO DE GREGORIO, Vice President, Head of Drug Safety Europe, Shionogi Europe
• RAJ BHOGAL, Senior Director, R&D Audits & Inspections, Jazz Pharmaceuticals
• FATIMA YOUSEF GHETHAN, Quality Culture & Implementation Manager, Executive Administration of Quality & Patient Safety, Makkah Healthcare Cluster (UAE)
• LUIZ LIMA, Senior Medical Director, Ipsen
• ANNA HELENA STAHL, Senior Director, Pharmacovigilance; EU QPPV, Bavarian Nordic
• ALINA TUDOR, Senior Director, Pharmacovigilance, Kyowa Kirin International
• ROHAN MANE, Director, Safety Risk Management Centre of Excellence, Pfizer
• ANDREA OLIVA, Head of Pharmacovigilance, Viatris
• DNYANESHWAR SANAP, EU/UK QPPV, Head Regional PV and Global Compliance & Training, Glenmark Pharmaceuticals
• VALENTINA MANCINI, Director PV, EU QPPV, Shionogi Europe
• TEA BABIC, Director, Head of Global PV Audits and Inspections, Deputy Head PV Compliance, Teva
• GRAEME LADDS, CEO, PharSafer
• DEEPA ARORA, Chief Executive Officer, CLINEXEL Life Sciences
• MIJAL CHAVDA, Global Head of GxP Inspection & GVP Quality, Kyowa Kirin
• ALESSANDRO VAGHEGGINI, Associate Principal Biostatistician, BARDS-CSS, MSD Merck Sharp & Dohme
• LUDIVINE DOUARIN, Benefit-Risk Expert, Sanofi
• TOMMASO VENTURI, Corporate Pharmacovigilance Risk Assessment Specialist, ITALFARMACO
• EMANUEL LOHRMANN, Lead Safety Physician, Otsuka Pharmaceutical
• KAPIL BHUTADA, Director, Pharmacovigilance Compliance and Training, Medicago
• KETAN MARULKAR, Senior Pharmacovigilance Officer, Chanelle Pharma
• ATTILA OLAH, Head of Global Patient Safety, Gedeon Richter
• DANIELA DI COSMO, Senior PV Manager, Global PV, Ferring Pharmaceuticals
• DARIUS-JEAN NAMDJOU, Head of Regulatory Affairs & Pharmacovigilance, Immunic Therapeutics
• GAURI UTTURKAR, Patient Safety Physician, UCB
• OLEKSANDR KARPENKO, Director, Olexacon
• MARIA BEATRICE PANICO, Principal Consultant, Scendea
• MARINA SUVAKOV, Global Head Product Safety Surveillance, Philip Morris International
• DIMITRIS ZAMPATIS, Global Program Safety Lead, Sandoz
• ALEXANDER ROUSSANOV, International Partner, Life Sciences and Privacy, Arnold & Porter

KEY THEMES DISCUSSED:

• Future of pharmacovigilance - Making medicines safe in an increasingly complex world
• Market analysis – Pharmacovigilance in 2023 - future horizons and efficiencies
• Refining the PV environment - Rising back from the pandemic
• Rethinking relationship between Sponsor, Site, CRO & Patients – Working together
• Why does pharmacovigilance sometimes fail and where could the fault lie?
• Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration
• Documentation (RMPs, PSURs, PADERs, PBRERs)
• Quality, Safety & Signal Detection – Overall approach
• From policy to practice: Prioritising Patients
• Developmental Risk management plans in Pharmacovigilance
• Impact of technology - Automation in Pharmacovigilance: A Closer look at use cases
• Plan, develop and implement the PV Audit strategy plan
• Medical devices – Increasing safety perspective
• Case studies from various countries on the PV frameworks around the world
• Prioritising Patients - Reshaping patient safety
• Brexit Implications for the Pharmaceutical (pharmacovigilance) Industry
• New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
• Regulatory - EU and UK Regulations & Guidelines in Pharmacovigilance
• Be part of a major networking opportunity

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.